🔴 Xenetic Biosciences is trading 6.1% down in pre-market over dilution concerns tied to proposed Santersus acquisition

Xenetic Biosciences is trading 6.1% down now at $2.31 as investors continue weighing the proposed all-stock acquisition of Santersus AG.

• Santersus shareholders would receive approximately 85% of the combined company, leaving existing Xenetic shareholders with about 15% ownership.
• No new company announcement dated September 18, 2026 was identified.
• The decline follows substantial volatility after the September 16 merger announcement, while broader pre-market sentiment remained modestly positive, suggesting company-specific dilution concerns are the stronger explanation.